High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.
CanSino Biologics' vaccine, approved for military use in China, is a modified form of adenovirus type 5, or Ad5. The company is in talks to get emergency approval in several countries before completing large-scale trials, the Wall Street Journal reported last week.
A vaccine developed by Moscow's Gamaleya Institute, approved in Russia earlier this month despite limited testing, is based on Ad5 and a second less common adenovirus.
"The Ad5 concerns me just because a lot of people have immunity," said Anna Durbin, a vaccine researcher at Johns Hopkins University. "I'm not sure what their strategy is ... maybe it won't have 70% efficacy. It might have 40% efficacy, and that's better than nothing, until something else comes along."
Vaccines are seen as essential to ending the pandemic that has claimed over 845,000 lives worldwide. Gamaleya has said its two-virus approach will address Ad5 immunity issues.
Both developers have years of experience and approved Ebola vaccines based on Ad5. Neither CanSino nor Gamaleya responded to requests for comment.
Researchers have experimented with Ad5-based vaccines against a variety of infections for decades, but none are widely used. They employ harmless viruses as "vectors" to ferry genes from the target virus – in this case the novel coronavirus - into human cells, prompting an immune response to fight the actual virus.
But many people already have antibodies against Ad5, which could cause the immune system to attack the vector instead of responding to the coronavirus, making these vaccines less effective.
Several researchers have chosen alternative adenoviruses or delivery mechanisms. Oxford University and AstraZeneca based their COVID-19 vaccine on a chimpanzee adenovirus, avoiding the Ad5 issue. Johnson & Johnson's candidate uses Ad26, a comparatively rare strain.
Dr. Zhou Xing, from Canada's McMaster University, worked with CanSino on its first Ad5-based vaccine, for tuberculosis, in 2011. His team is developing an inhaled Ad5 COVID-19 vaccine, theorizing it could circumvent pre-existing immunity issues.
"The Oxford vaccine candidate has quite an advantage" over the injected CanSino vaccine, he said.
Xing also worries that high doses of the Ad5 vector in the CanSino vaccine could induce fever, fueling vaccine skepticism.
"I think they will get good immunity in people that don't have antibodies to the vaccine, but a lot of people do," said Dr. Hildegund Ertl, director of the Wistar Institute Vaccine Center in Philadelphia.
In China and the United States, about 40% of people have high levels of antibodies from prior Ad5 exposure. In Africa, it could be has high as 80%, experts said.
HIV RISK
Some scientists also worry an Ad5-based vaccine could increase chances of contracting HIV.
In a 2004 trial of a Merck & Co Ad5-based HIV vaccine, people with pre-existing immunity became more, not less, susceptible to the virus that causes AIDS.
Researchers, including top U.S. infectious diseases expert Dr. Anthony Fauci, in a 2015 paper, said the side effect was likely unique to HIV vaccines. But they cautioned that HIV incidence should be monitored during and after trials of all Ad5-based vaccines in at-risk populations.
"I would be worried about the use of those vaccines in any country or any population that was at risk of HIV, and I put our country as one of them," said Dr. Larry Corey, co-leader of the U.S. Coronavirus Vaccine Prevention Network, who was a lead researcher on the Merck trial.
Gamaleya's vaccine will be administered in two doses: The first based on Ad26, similar to J&J's candidate, and the second on Ad5.
Alexander Gintsburg, Gamaleya's director, has said the two-vector approach addresses the immunity issue. Ertl said it might work well enough in individuals who have been exposed to one of the two adenoviruses.
Many experts expressed skepticism about the Russian vaccine after the government declared its intention to give it to high-risk groups in October without data from large pivotal trials.
"Demonstrating safety and efficacy of a vaccine is very important," said Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J's COVID-19 vaccine. Often, he noted, large-scale trials "do not give the result that is expected or required."
Reuters
Tue Sep 01 2020
A logo of China's vaccine specialist CanSino Biologics Inc is pictured on the company's headquarters in Tianjin, following an outbreak of the coronavirus disease (COVID-19), China August 17, 2020 - REUTERS/Thomas Peter
KDN muktamad pembelian empat helikopter untuk APMM bernilai RM600 juta
Kertas kerja bagi perolehan aset itu sudah diserahkan kepada Kementerian Kewangan untuk keputusan akhir.
Kempen PRK KKB lancar setakat ini - Polis Selangor
Kempen PRK DUN KKB yang memasuki hari ketiga hari ini berjalan lancar dan tiada sebarang insiden tidak diingini dilaporkan setakat ini.
Buletin AWANI Khas: Asia Barat sedang ‘Stress’: Dialog menteri-menteri dunia Arab
Situasi meruncing di Gaza, konflik Iran-Israel dan ditambah pula persaingan kuat dua kuasa, Amerika Syarikat dan China dilihat terus membayangi percaturan geopolitik dan geoekonomi negara-negara Islam di Asia Barat. Beberapa Menteri Luar negara-negara Arab duduk sepentas di Mesyuarat Khas WEF, Riyadh dalam sesi ini.
#SpecialMeeting24
#SpecialMeeting24
AWANI Ringkas: Projek NTC | Sindiket Dadah
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
Kilang cat terbakar, dua sekolah di Meru diarah ditutup
Penutupan dua buah sekolah terlibat iaitu SK Meru dan Sekolah Rendah Agama Meru 2 itu dibuat atas faktor keselamatan.
AWANI 7:45 [29/04/2024] – Meja bulat bersama 50 pemimpin industri dunia | Penggunaan komersial capai 80 peratus
PM yakin Malaysia jadi destinasi pelabur bernilai tinggi.
Kerajaan perkenal program solar untuk pengguna komersial.
Kelas Terapung dilaksana kawasan penduduk kepadatan tinggi.
Laporan Bank Dunia dedah hanya 58 peratus pelajar mahir membaca menjelang akhir darjah 5.
Kerajaan perkenal program solar untuk pengguna komersial.
Kelas Terapung dilaksana kawasan penduduk kepadatan tinggi.
Laporan Bank Dunia dedah hanya 58 peratus pelajar mahir membaca menjelang akhir darjah 5.
Malaysia perlu berani menentang Denmark
Hanya kemenangan menentang Denmark, kuasa besar badminton dunia, dalam aksi penting Kumpulan D Piala Thomas 2024 esok akan membawa Malaysia mendahului carta kedudukan.
Indonesia sokong pendekatan Malaysia bantu bangun 'peradaban' banduan Indonesia
Penjara bukan semata-mata tempat menghukum tetapi mentransformasikan ia sebagai institusi pendidikan yang memberi peluang kepada penghuni.
Polis tembak kereta mewah bawa dadah lebih RM100,000
Polis terpaksa melepaskan tembakan bagi mengawal keadaan selepas pemandu kenderaan terbabit bertindak agresif dan cuba merempuh anggota polis .
Polis siasat dakwaan pusat keagamaan di Nilai lakukan aktiviti mencurigakan
Ketua Polis Negeri Sembilan Datuk Ahmad Dzaffir Mohd Yussof berkata pihaknya menerima laporan berhubung perkara tersebut Jumat lepas.
124 kes HIV baharu di Johor - Exco
Sebanyak 313 kes HIV dilaporkan di Johor sejak Januari hingga hari ini, kata Pengerusi Jawatankuasa Kesihatan dan Perpaduan Negeri, Ling Tian Soon.
Johor catat 494 kes HIV, 244 kes AIDS sehingga minggu epid 24/2022
Johor Bahru melaporkan kes HIV baharu tertinggi iaitu 122 kes.
Jangkitan baharu HIV menurun 70 peratus dalam tempoh 20 tahun - KKM
Rawatan ubat antiretroviral kepada orang yang hidup dengan HIV telah dipertingkatkan kepada 66 peratus pada tahun lepas.
Hapuskan ketidaksamaan untuk lenyapkan AIDS -Dr Adeeba
Stigma dan diskriminasi menjadi penghalang yang tidak diperlukan kepada perkhidmatan rawatan, pencegahan dan penjagaan HIV.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Sebanyak 90 peratus penghidap HIV/AIDS adalah lelaki
Sebanyak 90 peratus penghidap HIV/AIDS di negara ini adalah terdiri daripada golongan lelaki, kata Ketua Sektor HIV/AIDS dan Hepatitis C Kementerian Kesihatan Dr Anita Suleiman.
MAF, Perkeso jalin kerjasama bantu pencarum HIV/AIDS
Pertubuhan Keselamatan Sosial (Perkeson) dan Yayasan Aids Malaysia (MAF) jalin kerjasama bagi memperkasakan ODHA dalam kalangan pencarum.
Pesakit AIDS juga manusia, dekati mereka. Agenda AWANI 9 malam ini
Akhiri ketidaksamaan layanan terhadap pesakit AIDS untuk kita bersama menangani penyakit tersebut.
Usaha tangani HIV/AIDS berdepan tekanan tatkala COVID-19 berlanjutan - Prof Adeeba
Antara cabaran lain termasuk kekuatan fizikal dan mental mereka yang menggerakkan inisiatif tersebut.
Agong bangga atas pelantikan Dr Adeeba sebagai anggota Majlis Sains WHO
Pakar penyakit berjangkit negara Prof Datuk Dr Adeeba Kamarulzaman atas pelantikan menjadi anggota Majlis Sains Pertubuhan Kesihatan Sedunia (WHO).